Perrigo Company plc (0Y5E.L)
USD 26.07
(-4.05%)
USD 26.07
(-4.05%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | 3.32 Billion USD | -5.24% |
| 2022 | 3.5 Billion USD | 111.76% |
| 2021 | 1.65 Billion USD | -43.39% |
| 2020 | 2.92 Billion USD | -3.0% |
| 2019 | 3.01 Billion USD | 12.02% |
| 2018 | 2.69 Billion USD | 1.08% |
| 2017 | 2.66 Billion USD | -48.55% |
| 2016 | 5.17 Billion USD | 14.34% |
| 2015 | 4.52 Billion USD | 85.89% |
| 2014 | 2.43 Billion USD | 103.89% |
| 2013 | 1.19 Billion USD | 55.72% |
| 2012 | 766.83 Million USD | 31.61% |
| 2011 | 582.66 Million USD | -53.25% |
| 2010 | 1.24 Billion USD | 116.38% |
| 2009 | 576.04 Million USD | -3.44% |
| 2008 | 596.58 Million USD | -7.88% |
| 2007 | 647.61 Million USD | 3.99% |
| 2006 | 622.78 Million USD | -6.32% |
| 2005 | 664.76 Million USD | 538.14% |
| 2004 | -151.72 Million USD | -78.82% |
| 2003 | -84.84 Million USD | -23.89% |
| 2002 | -68.48 Million USD | -4029.2% |
| 2001 | 1.74 Million USD | -4.7% |
| 2000 | 1.82 Million USD | -98.7% |
| 1999 | 140.3 Million USD | 64.09% |
| 1998 | 85.5 Million USD | 778.57% |
| 1997 | -12.6 Million USD | -125.77% |
| 1996 | 48.9 Million USD | -50.66% |
| 1995 | 99.1 Million USD | 39.58% |
| 1994 | 71 Million USD | -6.33% |
| 1993 | 75.8 Million USD | 63.36% |
| 1992 | 46.4 Million USD | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q1 | 3.58 Billion USD | 7.95% |
| 2024 Q2 | 3.7 Billion USD | 3.4% |
| 2023 Q1 | 3.54 Billion USD | -3.97% |
| 2023 FY | 3.32 Billion USD | -5.24% |
| 2023 Q3 | 3.48 Billion USD | -1.44% |
| 2023 Q2 | 3.53 Billion USD | -0.27% |
| 2023 Q4 | 3.32 Billion USD | -4.76% |
| 2022 FY | 3.5 Billion USD | 111.76% |
| 2022 Q3 | 3.64 Billion USD | 0.29% |
| 2022 Q2 | 3.63 Billion USD | 134.34% |
| 2022 Q1 | 1.54 Billion USD | -6.4% |
| 2022 Q4 | 3.69 Billion USD | 1.46% |
| 2021 Q3 | 1.47 Billion USD | -54.54% |
| 2021 Q1 | 3.09 Billion USD | 5.66% |
| 2021 Q4 | 1.65 Billion USD | 12.46% |
| 2021 FY | 1.65 Billion USD | -43.39% |
| 2021 Q2 | 3.23 Billion USD | 4.8% |
| 2020 Q1 | 2.96 Billion USD | -1.81% |
| 2020 Q2 | 2.68 Billion USD | -9.26% |
| 2020 Q4 | 2.92 Billion USD | 7.89% |
| 2020 Q3 | 2.71 Billion USD | 0.91% |
| 2020 FY | 2.92 Billion USD | -3.0% |
| 2019 Q4 | 3.01 Billion USD | -2.8% |
| 2019 Q2 | 2.56 Billion USD | 7.9% |
| 2019 Q1 | 2.37 Billion USD | -11.57% |
| 2019 FY | 3.01 Billion USD | 12.02% |
| 2019 Q3 | 3.1 Billion USD | 20.79% |
| 2018 Q3 | 2.82 Billion USD | 2.34% |
| 2018 Q2 | 2.75 Billion USD | 3.97% |
| 2018 Q4 | 2.69 Billion USD | -4.6% |
| 2018 Q1 | 2.65 Billion USD | -0.42% |
| 2018 FY | 2.69 Billion USD | 1.08% |
| 2017 Q1 | 2.71 Billion USD | -47.51% |
| 2017 FY | 2.66 Billion USD | -48.55% |
| 2017 Q4 | 2.66 Billion USD | -8.72% |
| 2017 Q3 | 2.91 Billion USD | 0.1% |
| 2017 Q2 | 2.91 Billion USD | 7.27% |
| 2016 Q2 | 5.76 Billion USD | -2.77% |
| 2016 Q3 | 5.54 Billion USD | -3.96% |
| 2016 Q4 | 5.17 Billion USD | -6.59% |
| 2016 FY | 5.17 Billion USD | 14.34% |
| 2016 Q1 | 5.93 Billion USD | 6.48% |
| 2015 FY | 4.52 Billion USD | 85.89% |
| 2015 Q3 | 4.86 Billion USD | 7.57% |
| 2015 Q4 | 5.57 Billion USD | 14.45% |
| 2015 Q2 | 4.52 Billion USD | 249.11% |
| 2015 Q1 | 1.29 Billion USD | 7.53% |
| 2014 FY | 2.43 Billion USD | 103.89% |
| 2014 Q2 | 2.43 Billion USD | -8.39% |
| 2014 Q4 | 1.2 Billion USD | -47.6% |
| 2014 Q3 | 2.3 Billion USD | -5.5% |
| 2014 Q1 | 2.65 Billion USD | -4.37% |
| 2013 Q1 | 1.07 Billion USD | 17.92% |
| 2013 FY | 1.19 Billion USD | 55.72% |
| 2013 Q4 | 2.77 Billion USD | 138.21% |
| 2013 Q3 | 1.16 Billion USD | -2.29% |
| 2013 Q2 | 1.19 Billion USD | 10.91% |
| 2012 FY | 766.83 Million USD | 31.61% |
| 2012 Q4 | 913.02 Million USD | 23.47% |
| 2012 Q3 | 739.44 Million USD | -3.57% |
| 2012 Q2 | 766.83 Million USD | -18.45% |
| 2012 Q1 | 940.34 Million USD | -2.16% |
| 2011 Q4 | 961.13 Million USD | -11.25% |
| 2011 Q1 | 668.38 Million USD | -11.61% |
| 2011 Q2 | 582.66 Million USD | -12.82% |
| 2011 Q3 | 1.08 Billion USD | 85.86% |
| 2011 FY | 582.66 Million USD | -53.25% |
| 2010 Q4 | 756.19 Million USD | -10.87% |
| 2010 Q2 | 1.24 Billion USD | 144.36% |
| 2010 Q1 | 510.07 Million USD | -5.47% |
| 2010 FY | 1.24 Billion USD | 116.38% |
| 2010 Q3 | 848.42 Million USD | -31.93% |
| 2009 Q4 | 539.57 Million USD | -7.99% |
| 2009 Q2 | 576.04 Million USD | -16.88% |
| 2009 Q3 | 586.44 Million USD | 1.81% |
| 2009 Q1 | 693.05 Million USD | -7.21% |
| 2009 FY | 576.04 Million USD | -3.44% |
| 2008 Q1 | 660.96 Million USD | 10.83% |
| 2008 Q3 | 665.26 Million USD | 11.51% |
| 2008 FY | 596.58 Million USD | -7.88% |
| 2008 Q2 | 596.58 Million USD | -9.74% |
| 2008 Q4 | 746.93 Million USD | 12.28% |
| 2007 Q1 | 693.14 Million USD | 7.05% |
| 2007 FY | 647.61 Million USD | 3.99% |
| 2007 Q2 | 647.61 Million USD | -6.57% |
| 2007 Q3 | 622.78 Million USD | -3.83% |
| 2007 Q4 | 596.39 Million USD | -4.24% |
| 2006 Q4 | 647.48 Million USD | -0.54% |
| 2006 Q3 | 650.98 Million USD | 4.53% |
| 2006 Q2 | 622.78 Million USD | 5.17% |
| 2006 Q1 | 592.16 Million USD | -7.49% |
| 2006 FY | 622.78 Million USD | -6.32% |
| 2005 Q3 | 664.99 Million USD | 0.04% |
| 2005 Q4 | 640.09 Million USD | -3.75% |
| 2005 Q2 | 664.76 Million USD | -0.53% |
| 2005 Q1 | 668.3 Million USD | 502.73% |
| 2005 FY | 664.76 Million USD | 538.14% |
| 2004 Q2 | -151.72 Million USD | -3.45% |
| 2004 FY | -151.72 Million USD | -78.82% |
| 2004 Q3 | -127.07 Million USD | 16.24% |
| 2004 Q4 | -165.94 Million USD | -30.58% |
| 2004 Q1 | -146.67 Million USD | -42.81% |
| 2003 Q2 | -84.84 Million USD | 12.07% |
| 2003 Q3 | -75.85 Million USD | 10.6% |
| 2003 Q1 | -96.49 Million USD | -54.87% |
| 2003 FY | -84.84 Million USD | -23.89% |
| 2003 Q4 | -102.7 Million USD | -35.39% |
| 2002 Q4 | -62.3 Million USD | -53.89% |
| 2002 Q2 | -68.48 Million USD | -133.32% |
| 2002 Q1 | -29.35 Million USD | -495.75% |
| 2002 FY | -68.48 Million USD | -4029.2% |
| 2002 Q3 | -40.48 Million USD | 40.89% |
| 2001 Q4 | 7.41 Million USD | -75.33% |
| 2001 Q3 | 30.06 Million USD | 1624.73% |
| 2001 Q2 | 1.74 Million USD | 102.9% |
| 2001 Q1 | -60.12 Million USD | -40.1% |
| 2001 FY | 1.74 Million USD | -4.7% |
| 2000 FY | 1.82 Million USD | -98.7% |
| 2000 Q2 | 1.82 Million USD | -94.54% |
| 2000 Q1 | 33.48 Million USD | -64.07% |
| 2000 Q4 | -42.91 Million USD | -71.07% |
| 2000 Q3 | -25.08 Million USD | -1471.68% |
| 1999 FY | 140.3 Million USD | 64.09% |
| 1999 Q3 | 121.1 Million USD | -13.68% |
| 1999 Q4 | 93.2 Million USD | -23.04% |
| 1999 Q2 | 140.3 Million USD | -17.52% |
| 1999 Q1 | 170.1 Million USD | -4.6% |
| 1998 Q4 | 178.3 Million USD | 31.2% |
| 1998 Q3 | 135.9 Million USD | 58.95% |
| 1998 FY | 85.5 Million USD | 778.57% |
| 1998 Q2 | 85.5 Million USD | 36.36% |
| 1998 Q1 | 62.7 Million USD | 5.91% |
| 1997 Q4 | 59.2 Million USD | 179.25% |
| 1997 FY | -12.6 Million USD | -125.77% |
| 1997 Q3 | 21.2 Million USD | 268.25% |
| 1997 Q2 | -12.6 Million USD | -162.5% |
| 1997 Q1 | -4.8 Million USD | -141.74% |
| 1996 FY | 48.9 Million USD | -50.66% |
| 1996 Q1 | 67.9 Million USD | -32.03% |
| 1996 Q2 | 48.9 Million USD | -27.98% |
| 1996 Q3 | 41.6 Million USD | -14.93% |
| 1996 Q4 | 11.5 Million USD | -72.36% |
| 1995 Q3 | 98.2 Million USD | -0.91% |
| 1995 Q2 | 99.1 Million USD | -1.1% |
| 1995 Q1 | 100.2 Million USD | 22.05% |
| 1995 FY | 99.1 Million USD | 39.58% |
| 1995 Q4 | 99.9 Million USD | 1.73% |
| 1994 Q4 | 82.1 Million USD | 5.39% |
| 1994 FY | 71 Million USD | -6.33% |
| 1994 Q1 | 75.1 Million USD | -16.56% |
| 1994 Q2 | 71 Million USD | -5.46% |
| 1994 Q3 | 77.9 Million USD | 9.72% |
| 1993 Q3 | 77.4 Million USD | 2.11% |
| 1993 FY | 75.8 Million USD | 63.36% |
| 1993 Q1 | 78.1 Million USD | 31.04% |
| 1993 Q2 | 75.8 Million USD | -2.94% |
| 1993 Q4 | 90 Million USD | 16.28% |
| 1992 Q3 | 61 Million USD | 31.47% |
| 1992 Q1 | 41.6 Million USD | 292.59% |
| 1992 FY | 46.4 Million USD | 0.0% |
| 1992 Q2 | 46.4 Million USD | 11.54% |
| 1992 Q4 | 59.6 Million USD | -2.3% |
| 1991 Q4 | -21.6 Million USD | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| uniQure N.V. | -102.95 Million USD | 3326.875% |
| Agios Pharmaceuticals, Inc. | -31.21 Million USD | 10741.958% |
| Amicus Therapeutics, Inc. | 198.06 Million USD | -1577.278% |
| Atara Biotherapeutics, Inc. | 31.88 Million USD | -10319.006% |
| bluebird bio, Inc. | 108.57 Million USD | -2959.841% |
| Cara Therapeutics, Inc. | -9.01 Million USD | 36946.717% |
| Imunon, Inc. | -4.69 Million USD | 70793.914% |
| Editas Medicine, Inc. | -87.11 Million USD | 3913.421% |
| IQVIA Holdings Inc. | 12.85 Billion USD | 74.157% |
| Mettler-Toledo International Inc. | 2.09 Billion USD | -58.349% |
| Myriad Genetics, Inc. | 88.1 Million USD | -3670.829% |
| Neurocrine Biosciences, Inc. | 177.3 Million USD | -1773.717% |
| Supernus Pharmaceuticals, Inc. | -33.52 Million USD | 10008.73% |
| Verastem, Inc. | -37.27 Million USD | 9011.691% |
| Walgreens Boots Alliance, Inc. | 8.23 Billion USD | 59.659% |
| Waters Corporation | 1.96 Billion USD | -69.457% |
| Thermo Fisher Scientific Inc. | 26.84 Billion USD | 87.623% |
| Biogen Inc. | 6.28 Billion USD | 47.17% |
| Nektar Therapeutics | 210.24 Million USD | -1480.146% |
| Dynavax Technologies Corporation | 106.63 Million USD | -3015.394% |
| Illumina, Inc. | 1.21 Billion USD | -173.649% |
| Corbus Pharmaceuticals Holdings, Inc. | 6.96 Million USD | -47576.001% |
| Iovance Biotherapeutics, Inc. | -113.88 Million USD | 3016.989% |
| Heron Therapeutics, Inc. | 145.07 Million USD | -2189.903% |
| Unity Biotechnology, Inc. | 7.18 Million USD | -46123.737% |
| BioMarin Pharmaceutical Inc. | 378.74 Million USD | -777.127% |
| Sangamo Therapeutics, Inc. | -7.1 Million USD | 46890.141% |
| Evolus, Inc. | 63.7 Million USD | -5114.573% |
| Adicet Bio, Inc. | -142 Million USD | 2439.375% |
| Aclaris Therapeutics, Inc. | -36.8 Million USD | 9126.465% |
| Regeneron Pharmaceuticals, Inc. | -27.1 Million USD | 12358.672% |
| Esperion Therapeutics, Inc. | 458.69 Million USD | -624.244% |
| FibroGen, Inc. | 56.76 Million USD | -5752.168% |
| Agilent Technologies, Inc. | 1.14 Billion USD | -190.14% |
| OPKO Health, Inc. | 230.68 Million USD | -1340.115% |
| Homology Medicines, Inc. | 18.43 Million USD | -17918.658% |
| Geron Corporation | 14.76 Million USD | -22405.928% |
| Alnylam Pharmaceuticals, Inc. | 1.58 Billion USD | -109.553% |
| Exelixis, Inc. | -73.05 Million USD | 4647.707% |
| Viking Therapeutics, Inc. | -54.25 Million USD | 6223.009% |
| Anavex Life Sciences Corp. | -151.02 Million USD | 2299.717% |
| Intellia Therapeutics, Inc. | -111.4 Million USD | 3082.083% |
| Zoetis Inc. | 4.76 Billion USD | 30.237% |
| Axsome Therapeutics, Inc. | -199.82 Million USD | 1762.538% |
| Abeona Therapeutics Inc. | -10.07 Million USD | 33086.794% |
| Vertex Pharmaceuticals Incorporated | -9.56 Billion USD | 134.736% |
| Kala Pharmaceuticals, Inc. | -14.57 Million USD | 22897.831% |
| Ionis Pharmaceuticals, Inc. | 1.05 Billion USD | -215.108% |
| Sarepta Therapeutics, Inc. | 968.37 Million USD | -243.058% |
| Corcept Therapeutics Incorporated | -135.4 Million USD | 2553.545% |
| Halozyme Therapeutics, Inc. | 1.38 Billion USD | -140.579% |
| Blueprint Medicines Corporation | 702.83 Million USD | -372.671% |
| Insmed Incorporated | 721.62 Million USD | -360.367% |
| TG Therapeutics, Inc. | 17.86 Million USD | -18498.701% |
| Incyte Corporation | -3.17 Billion USD | 204.63% |
| Emergent BioSolutions Inc. | 765.8 Million USD | -333.808% |